Most Read Articles
Roshini Claire Anthony, 06 Oct 2020

Several strategies have been proposed to help manage the adverse events (AEs) that emerged during the BEACON CRC trial which assessed the effect of encorafenib plus cetuximab in patients with BRAF V600E mutant metastatic colorectal cancer (mCRC) who had progressed after one or two prior regimens.

Pearl Toh, 15 Nov 2020
Switching to a dual therapy of dolutegravir/lamivudine (DTG/3TC) was noninferior to continuing on a TAF*-based regimen in maintaining virologic suppression over 96 weeks in virally suppressed adults with HIV-1, according to the long-term data from TANGO presented at the 2020 HIV Glasgow Congress.

Oseltamivir cuts recovery time for flu in real world

Pearl Toh
31 Dec 2019

Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.

“Antivirals are infrequently prescribed in European primary care … mostly because of perceived ineffectiveness in real world primary care and because individuals who will especially benefit have not been identified in independent trials,” said the researchers.

“Whether treatment should be initiated only after a positive test for influenza or whether it should be based on syndromic presentation alone is unclear,” they added.

The real-world ALIC4E study showed that patients treated with oseltamivir were able to return to their usual daily activities with minimal/no residual symptoms one day sooner on average compared with those receiving usual care alone (absolute mean benefit, 1.02 days, 95 percent Bayesian credible interval [BCrI], 1.20–1.39). The corresponding hazard ratio (HR) for the overall population was 1.29 (95 percent BCrI, 1.20–1.39), indicating a shorter recovery with oseltamivir.

In particular, high-risk patients such as those aged 65 years, with comorbidities, had moderate-to-severe symptoms, and previously had symptom lasting 48 hours recovered 2–3 days sooner than patients managed by usual care alone (absolute mean benefit, 3.2 days, 95 percent BCrI, 1.00–5.50).

“Clinicians might consider treatment in patients who are sicker or older, who have comorbidities, and who have been unwell for longer, because oseltamivir might reduce their illness by as much as 2–3 days,” suggested the researchers.

Consistent benefit

Participants in the open-label, pragmatic trial were 3,266 patients aged 1 year (80 percent aged 12–65 years) presenting with influenza-like illness in primary care (52 percent with PCR-confirmed influenza infection). They were randomized 1:1 to receive oseltamivir plus usual care or usual care alone. [Lancet 2019;doi:10.1016/S0140-6736(19)32982-4]  

Across 36 prespecified subgroups (defined by age, symptom severity, comorbidity, and previous symptom duration) that the study was powered for, the primary endpoint of recovery time* was consistently shorter with oseltamivir over usual care alone (HRs ranging from 1.13 to 1.72).

“In general, more absolute benefit of oseltamivir was observed with increasing age, more severe illness, comorbidity, and when presenting after 48 hours,” the researchers noted.

“A possible explanation for the observation of the greatest effect in subgroups who were older and at higher risk is that viral replication continues for longer, with a longer natural history of the illness in such individuals,” they explained.

In addition, oseltamivir benefit was similar regardless of whether the patients had PCR-confirmed influenza infection (HR, 1.27, 95 percent BCrI, 1.15–1.41) or they were tested negative (HR, 1.31, 95 percent BCrI, 1.18–1.46).

There were no differences between the two group in the incidence of pneumonia, hospitalization, and use of healthcare services or over-the-counter medication containing ibuprofen or acetaminophen.

In terms of safety, there were more incidence of vomiting or nausea in the oseltamivir group than the usual care group (21 percent vs 16 percent), which the researchers said was a common side effect of oseltamivir.

Evidence for more widespread use?

“Although the average benefit for many patients is modest, and advocation of widespread use of oseltamivir is difficult owing to concerns about possible side effects and the medicalization of a largely self-limiting illness, clinicians and patients might wish to consider adding oseltamivir to routine treatment where a day less of illness is particularly important for patients,” said the researchers, alluding to high-risk patients.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 06 Oct 2020

Several strategies have been proposed to help manage the adverse events (AEs) that emerged during the BEACON CRC trial which assessed the effect of encorafenib plus cetuximab in patients with BRAF V600E mutant metastatic colorectal cancer (mCRC) who had progressed after one or two prior regimens.

Pearl Toh, 15 Nov 2020
Switching to a dual therapy of dolutegravir/lamivudine (DTG/3TC) was noninferior to continuing on a TAF*-based regimen in maintaining virologic suppression over 96 weeks in virally suppressed adults with HIV-1, according to the long-term data from TANGO presented at the 2020 HIV Glasgow Congress.